A group of people posing for a photo

About us

Mission and vision

It is our vision to identify scalable biosignatures for early and accurrate diagnosis of Alzheimer's Disease and personalized presentive interventions.

PREDICTOM aims to establish scalable, cost-efficient diagnostic markers, tools and procedures that can identify people at increased risk, at point of care for stratification into personalized interventions to prevent or delay dementia. 

PREDICTOM will develop an open-source, interoperable and customisable biomarker screening platform, utilizing an existing online resource to save time and money, to generate an evidence base for general population screening for AD and related disorders. 

PREDICTOM will bring diagnostics closer to the patient by examining the feasibility of using samples which can be obtained at home (e.g. finger-prick blood, saliva (for genetics and epigenetics) and stool (for microbiom) for diagnostic biomarker analysis. 

PREDICTOM will also evaluate innovative technologies for disease risk identification, including digital technologies and novel MRI, EEG, eye tracking, and bloodbased biomarkers. Our platform will use artificial intelligence models to analyse data from all biomarkers to identify users at high risk of developing dementia and to direct them to personalized intervention to prevent further cognitive decline and development of dementia. 

PREDICTOM will seek to facilitate a change in current healthcare practice for early diagnosis of AD through development of new clinical practice guidelines based on evidence generated in the project. 

PREDICTOM will by improving the ease of identification of those with early signs of dementia, we expect to have a significant impact on personal and financial burden of dementia in Europe and across the world.


Last updated 11/15/2023